Target Name: RNF2
NCBI ID: G6045
Review Report on RNF2 Target / Biomarker Content of Review Report on RNF2 Target / Biomarker
RNF2
Other Name(s): RING finger protein BAP-1 | HIPI3 | RING2 | protein DinG | RING-type E3 ubiquitin transferase RING2 | BAP-1 | LUSYAM | Protein DinG | RING finger protein 1B | E3 ubiquitin-protein ligase RING2 | RING finger protein 2 | RING1B | Huntingtin-interacting protein 2-interacting protein 3 | DING | HIP2-interacting protein 3 | huntingtin-interacting protein 2-interacting protein 3 | ring finger protein 2 | Ring finger protein 2 | RING2_HUMAN | RING1b | BAP1

The Potential Drug Target RNF2: Unlocking the Functional Role of RING finger Protein BAP-1

RING finger protein BAP-1, also known as RNA-protein BAP-1, is a key regulator of gene expression and has been implicated in various cellular processes. Its function in cell biology has been extensively studied, and it has been identified as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. In this article, we will explore the potential drug target nature of RNF2 and its clinical implications.

The RNA-protein BAP-1 (RING finger protein BAP-1) is a non-coding RNA molecule that plays a crucial role in gene regulation and translation. It is composed of a 23 amino acid protein coded from the RNA gene ATGACCTGACCTAA in humans, and it contains a unique feature known as a ring finger domain, which is a common structural motif found in proteins that interact with RNA. The ring finger domain is responsible for the formation of a double-stranded RNA structure, which can interact with other RNA molecules and regulate gene expression.

BAP-1 functions as a negative regulator of gene expression by binding to specific target genes and preventing their translation into protein. It does this by forming a double-stranded RNA structure with a specific secondary structure, which prevents the target gene from being translated into protein. Additionally, BAP-1 can also interact with other RNA molecules, such as microRNAs, and prevent them from being processed and degraded. This interaction between BAP-1 and other RNAs is known as post-transcriptional regulation, and it is a critical mechanism for regulating gene expression in various cell types.

The potential drug target nature of BAP-1 has been extensively studied, and several studies have identified its involvement in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. One of the most significant findings is that BAP-1 has been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that targeting BAP-1 may be an effective way to treat these cancers.

Another study has shown that BAP-1 is highly expressed in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that targeting BAP-1 may be an effective way to treat these diseases, which are currently treated with limited options.

In addition to its involvement in cancer and neurodegenerative diseases, BAP-1 has also been implicated in the development and progression of various developmental disorders. For example, one study has shown that BAP-1 is highly expressed in the brains of individuals with Down syndrome, and this suggests that targeting BAP-1 may be an effective way to treat this disorder.

Despite the potential benefits of targeting BAP-1, there are also potential drawbacks to consider. One of the main concerns is the potential off-target effects of BAP-1, which may lead to unintended consequences. Additionally, the regulation of BAP-1 by post-transcriptional regulation means that it is difficult to study its effects using traditional methods of gene editing, such as RNA interference or CRISPR/Cas9.

Conclusion

In conclusion, RNF2 (RING finger protein BAP-1) is a key regulator of gene expression and has been shown to be involved in various cellular processes. Its function in cell biology has been extensively studied, and it has been identified as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Further research is needed to fully understand the effects of targeting BAP-1 and to develop effective treatments for these diseases.

Protein Name: Ring Finger Protein 2

Functions: E3 ubiquitin-protein ligase that mediates monoubiquitination of 'Lys-119' of histone H2A (H2AK119Ub), thereby playing a central role in histone code and gene regulation (PubMed:15386022, PubMed:16359901, PubMed:25519132, PubMed:33864376, PubMed:21772249, PubMed:25355358, PubMed:26151332). H2AK119Ub gives a specific tag for epigenetic transcriptional repression and participates in X chromosome inactivation of female mammals. May be involved in the initiation of both imprinted and random X inactivation (By similarity). Essential component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development (PubMed:16359901, PubMed:26151332). PcG PRC1 complex acts via chromatin remodeling and modification of histones, rendering chromatin heritably changed in its expressibility (PubMed:26151332). E3 ubiquitin-protein ligase activity is enhanced by BMI1/PCGF4 (PubMed:21772249). Acts as the main E3 ubiquitin ligase on histone H2A of the PRC1 complex, while RING1 may rather act as a modulator of RNF2/RING2 activity (Probable). Association with the chromosomal DNA is cell-cycle dependent. In resting B- and T-lymphocytes, interaction with AURKB leads to block its activity, thereby maintaining transcription in resting lymphocytes (By similarity). Also acts as a negative regulator of autophagy by mediating ubiquitination of AMBRA1, leading to its subsequent degradation (By similarity)

The "RNF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25 | RNF26 | RNF31 | RNF32 | RNF32-DT | RNF34 | RNF38 | RNF39 | RNF4 | RNF40 | RNF41 | RNF43 | RNF44 | RNF5 | RNF5P1 | RNF6 | RNF7 | RNF7P1 | RNF8 | RNFT1 | RNFT2 | RNGTT | RNH1 | RNLS | RNMT | RNPC3 | RNPC3-DT | RNPEP | RNPEPL1 | RNPS1 | RNPS1P1 | RNR1 | RNR2 | RNU1-1 | RNU1-100P | RNU1-108P | RNU1-11P | RNU1-134P | RNU1-18P | RNU1-3 | RNU1-31P | RNU1-32P | RNU1-36P | RNU1-38P | RNU1-4 | RNU1-42P | RNU1-55P | RNU1-61P | RNU1-63P | RNU1-72P | RNU1-73P | RNU1-78P | RNU1-7P | RNU1-82P | RNU1-88P | RNU105B | RNU11 | RNU12 | RNU2-1 | RNU2-17P | RNU2-2P | RNU2-4P | RNU2-54P | RNU2-5P | RNU2-6P | RNU4-1 | RNU4-14P | RNU4-2 | RNU4-30P | RNU4-33P | RNU4-38P | RNU4-39P | RNU4-46P | RNU4-53P | RNU4-62P | RNU4-6P | RNU4-76P | RNU4-82P | RNU4-87P | RNU4-91P